Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
The Journal of Clinical Endocrinology & Metabolism · 18.10.2023 · 108 (11) · 2990-2998
DOI: 10.1210/clinem/dgad230 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 21.04.2023. Verfasst von Erik A Imel und 20 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Hypophosphatemia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ultragenyx Pharmaceutical Inc.
Abstract (Originalsprache)
Context
In an open-label, randomized, controlled, phase 3 trial in 61 children aged 1 to 12 years with X-linked hypophosphatemia (XLH), burosumab improved rickets vs continuing conventional therapy with active vitamin D and phosphate.
Objective
We conducted an analysis to determine whether skeletal responses differed when switching to burosumab vs continuing higher or lower doses of conventional therapy.
Methods
Conventional therapy dose groups were defined as higher-dose phosphate [greater than 40 mg/kg] (HPi), lower-dose phosphate [40 mg/kg or less] (LPi), higher-dose alfacalcidol [greater than 60 ng/kg] or calcitriol [greater than 30 ng/kg] (HD), and lower-dose alfacalcidol [60 ng/kg or less] or calcitriol [30 ng/kg or less] (LD).
Results
At week 64, the Radiographic Global Impression of Change (RGI-C) for rickets was higher (better) in children randomly assigned to burosumab vs conventional therapy for all prebaseline dose groups: HPi (+1.72 vs +0.67), LPi (+2.14 vs +1.08), HD (+1.90 vs +0.94), LD (+2.11 vs +1.06). At week 64, the RGI-C for rickets was also higher in children randomly assigned to burosumab (+2.06) vs conventional therapy for all on-study dose groups: HPi (+1.03), LPi (+1.05), HD (+1.45), LD (+0.72). Serum alkaline phosphatase (ALP) also decreased in the burosumab-treated patients more than in the conventional therapy group, regardless of on-study phosphate and active vitamin D doses.
Conclusion
Prior phosphate or active vitamin D doses did not influence treatment response after switching to burosumab among children with XLH and active radiographic rickets. Switching from conventional therapy to burosumab improved rickets and serum ALP more than continuing either higher or lower doses of phosphate or active vitamin D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Medicine and Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- Emeritus Director of Research, Shriners Hospitals for Children-Canada, Montreal, QC H4A 0A9, Canada.
- Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children-St. Louis, St Louis, MO 63110, USA.
- Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94115, USA.
- The University of Queensland, Queensland Children's Hospital, South Brisbane, QLD 4101, Australia.
- Division of Pediatric Endocrinology and Center for Molecular Medicine, Department of Women's and Children's Health, Karolinska Institutet and University Hospital, Stockholm 171 64, Sweden.
ORCID-Profile: Erik A Imel, Etienne Sochett, Gary S Gottesman
Förderung
- Ultragenyx Pharmaceutical Inc
Zitieren
APA
Imel, E. A., Glorieux, F. H., Whyte, M. P., Portale, A. A., Munns, C. F., Nilsson, O., Simmons, J. H., Padidela, R., Namba, N., Cheong, H. I., Pitukcheewanont, P., Sochett, E., Högler, W., Muroya, K., Tanaka, H., Gottesman, G. S., Biggin, A., Perwad, F., Chen, A., …, & Ward, L. M. (2023). Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level. The Journal of Clinical Endocrinology & Metabolism, 108(11), 2990-2998. https://doi.org/10.1210/clinem/dgad230
Vancouver
Imel EA, Glorieux FH, Whyte MP, Portale AA, Munns CF, Nilsson O, et al. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level. The Journal of Clinical Endocrinology & Metabolism. 2023;108(11):2990-2998. doi:10.1210/clinem/dgad230
BibTeX
@article{Imel2023,
author = {Imel, Erik A and Glorieux, Francis H and Whyte, Michael P and Portale, Anthony A and Munns, Craig F and Nilsson, Ola and Simmons, Jill H and Padidela, Raja and Namba, Noriyuki and Cheong, Hae Il and Pitukcheewanont, Pisit and Sochett, Etienne and Högler, Wolfgang and Muroya, Koji and Tanaka, Hiroyuki and Gottesman, Gary S and Biggin, Andrew and Perwad, Farzana and Chen, Angel and Roberts, Mary Scott and Ward, Leanne M},
title = {Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {11},
pages = {2990--2998},
doi = {10.1210/clinem/dgad230}
}
EUVIMED